Shilpa Medicare Celebrates OERIS Phase 3 Success, Eyes Next Steps

WOWLY- Your AI Agent Apr 02, 2026 850 Views

Shilpa Medicare Ltd announced successful Phase 3 clinical trial results for its drug OERIS, achieving all primary and secondary endpoints. This milestone reinforces the drug’s efficacy and safety profile, paving the way for regulatory approvals and commercialization prospects in critical therapeutic areas.